NPM1 and acute myeloid leukemia: Though it is well established that mutated NPM1 has favorable outcomes in AML, our results and the above studies suggest that DMRGM may adversely impact the OS of patients with mutated NPM1. Although many of the above studies considered the effects of cytogenetic findings and NPM1 mutation, none of these studies specifically looked into the impact of these gene mutations among different ELN risk groups.